TY - JOUR T1 - Effect of celastrol on bone structure and mechanics in arthritic rats JF - RMD Open JO - RMD Open DO - 10.1136/rmdopen-2017-000438 VL - 3 IS - 2 SP - e000438 AU - Rita Cascão AU - Bruno Vidal AU - Mikko Arttu Jalmari Finnilä AU - Inês Pascoal Lopes AU - Rui Lourenço Teixeira AU - Simo Saarakkala AU - Luis Ferreira Moita AU - João Eurico Fonseca Y1 - 2017/09/01 UR - http://rmdopen.bmj.com/content/3/2/e000438.abstract N2 - Objective Rheumatoid arthritis (RA) is characterised by chronic inflammation leading to articular bone and cartilage damage. Despite recent progress in RA management, adverse effects, lack of efficacy and economic barriers to treatment access still limit therapeutic success. Therefore, safer and less expensive treatments that control inflammation and bone resorption are needed. We have previously shown that celastrol is a candidate for RA treatment. We have observed that it inhibits both interleukin (IL)-1β and tumor necrosis factor (TNF) in vitro, and that it has anti-inflammatory properties and ability to decrease synovial CD68+ macrophages in vivo. Herein our goal was to evaluate the effect of celastrol in local and systemic bone loss.Methods Celastrol was administrated intraperitoneally at a dose of 1 µg/g/day to female Wistar adjuvant-induced arthritic rats. Rats were sacrificed after 22 days of disease progression, and blood, femurs, tibiae and paw samples were collected for bone remodelling markers quantification, 3-point bending test, micro-CT analysis, nanoindentation and Fourier transform infrared spectroscopy measurements, and immunohistochemical evaluation.Results We have observed that celastrol preserved articular structures and decreased the number of osteoclasts and osteoblasts present in arthritic joints. Moreover, celastrol reduced tartrate-resistant acid phosphatase 5b, procollagen type 1 amino-terminal propeptide and C terminal crosslinked telopeptide of type II collagen serum levels. Importantly, celastrol prevented bone loss and bone microarchitecture degradation. Celastrol also preserved bone nanoproperties and mineral content. Additionally, animals treated with celastrol had less fragile bones, as depicted by an increase in maximum load and yield displacement.Conclusions These results suggest that celastrol reduces both bone resorption and cartilage degradation, and preserves bone structural properties. ER -